Randomized Phase II Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 119
- 试验地点
- 1
- 主要终点
- Progression free survival (PFS)
研究概览
简要总结
Multicenter Phase II study on Decitabine-Carboplatin combination in platinum resistant ovarian cancer patients.
Patients will receive study treatment until disease progression is documented, extraordinary medical circumstances occur, intolerable toxicities occur, or the patient withdraws consent.
详细描述
This is an open-label, prospective, multicenter, randomized Phase II, clinical trial evaluating the efficacy and safety of Decitabine-Carboplatin combination in recurrent, platinum resistant ovarian cancer patients in comparison to physician' choice chemotherapy:
Arm A: Carboplatin AUC (Area Under Curve) 5 d 8 q 28 Plus Decitabine 10 mg/mq iv d1-5 q 28
Arm B: Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/mq gg 1, 8, 15 q 28
Patients will be randomly assigned in a 1:1 ratio to treatment arms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Cytologic / histologic diagnosis of stage 1°C-4° epithelial , fallopian tube and primary peritoneal cancer (carcinosarcomas are included)
- •Patient who received 1-2 prior lines of treatments
- •Patient relapsed within 6 months after platinum containing regimen
- •Disease measurable or evaluable by RECIST version 1.1 or Ca 125 GCIG criteria (Gynaecologic Cancer Intergroup).
- •No residual peripheral neurotoxicity > Grade 1 from previous chemotherapy treatment
- •Performance Status (PS) 0-1
- •Age 18 years.
- •Life expectancy of at least 3 months
- •Written informed consent prior to performance of study specific procedures or assessments
- •Ability and willingness to comply with treatment and follow up assessments and procedures
- •Adequate organ functions:
- •Hematopoietic: Leukocytes > 2,500/mm3; Absolute neutrophil count >1,500/mm3; Platelets count >100,000/mm3; Hemoglobin >9 g/dL
- •Hepatic: AST (aspartate transaminase ) and ALT (alanine transaminase) <3 times upper limit of normal (ULN)*; Alkaline phosphatase <3 times ULN*; Bilirubin <1.5 times ULN
- •*: <5 times ULN if liver metastases are present
- •Renal: Creatinine clearance >45 mL/min
- •No other invasive malignancy within the past 3 years except non-melanoma skin cancer and in situ cervical cancer
- •Absence of any psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol and follow-up schedule.
排除标准
- •Pregnant (potentially fertile patients must use contraceptive measures to avoid pregnancy during and for at least 3 months after study participation and must have a negative serum pregnancy test at baseline).
- •Patients should not be breast-feeding during treatment and for 2 months following the end of treatment.
- •Serious heart disease, including heart failure, atrio-ventricular block of any degree, serious arrhythmia or history of any one or more of the following cardiovascular conditions within the past 6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina, symptomatic peripheral vascular disease, coronary artery by-pass graft surgery, class II, III or IV congestive heart failure as defined by the New York Heart Association (NYHA)
- •Active infection requiring antibiotics.
- •History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
- •History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.
- •Patients who had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. Note: Subjects with < Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study.
- •Patients with evidence of interstitial lung disease.
- •Major surgical procedure, open biopsy, or significant traumatic injury within 3 weeks prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study; minor surgical procedures such as fine needle aspiration or core biopsy within 1 week prior to beginning therapy are also excluded.
- •Known hypersensitivity to the study drugs or to drugs with similar chemical structures.
- •Concurrent treatment with other experimental drugs.
- •Participation in another clinical trial with any investigational drug within 30 days prior to study screening.
研究组 & 干预措施
Decitabine plus Carboplatin
Carboplatin AUC 5 d 8 q 28 plus Decitabine 10 mg/mq iv d1-5 q 28
干预措施: Decitabine (Drug)
Decitabine plus Carboplatin
Carboplatin AUC 5 d 8 q 28 plus Decitabine 10 mg/mq iv d1-5 q 28
干预措施: Carboplatin (Drug)
Standard Treatment
Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28
干预措施: Pegylated Liposomal Doxorubicin (Drug)
Standard Treatment
Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28
干预措施: Gemcitabine (Drug)
Standard Treatment
Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28
干预措施: Paclitaxel (Drug)
结局指标
主要结局
Progression free survival (PFS)
时间窗: from randomization to the date of radiological/clinical progression of disease or death, assessed up to 3 years
The primary objective is to compare Decitabine plus Carboplatin combination versus physician' choice chemotherapy in terms of progression free survival
次要结局
- Overall survival (OS)(from randomization to the date of death, assessed up to 3 years)
- Radiological response rate (in patients with measurable disease)(3 years)
- Duration of response(3 years)
- Cancer-Antigen 125 (CA-125) response rate per GCIG (Gynaecologic Cancer Intergroup) and change in CA-125(3 years)
- Toxicity profile(3 years)
- Patient Reported Outcome: Physical well-being(3 years)
- Patient Reported Outcome: Social/family well-being(3 years)
- Patient Reported Outcome: Functional well being(3 years)
- Patient Reported Outcome: Emotional well being(3 years)